Table 3. HRs for mortality or disease recurrence by presence of anti-HPV antibodies.

Antibodies/tumor DNA	Overall mortality, HR (95% CI)	Disease-specific mortality, HR (95% CI)	Disease recurrence, HR (95% CI)
HPV-16 VLP	0.4 (0.2-0.8)	0.4 (0.1-0.9)	0.6 (0.2-1.5)*
HPV-16 E6	0.1 (0.04-0.5)	0.1 (0.02-0.5)	0.3 (0.1-1.5)†
HPV-16 E7	0.4 (0.1-0.9)	0.3 (0.1-0.9)	0.2 (0.02-1.4)†
HPV-16 E6 and/or E7	0.3 (0.1-0.7)	0.3 (0.1-0.9)	0.5 (0.1-1.7)*
HPV-16 E6 and E7	0.2 (0.1-0.6)	0.1 (0.03-0.7)	— ‡
HPV DNA+	0.2 (0.1-0.6)	0.2 (0.1-0.7)	0.6 (0.2-2.0)*

NOTE: HRs adjusted for age, gender, stage of disease, tumor grade, histology, surgery, and radiation; reference group includes those negative for the HPV antibody examined.

^*P > 0.20.

^†P ≥ 0.10.

^‡HR not estimable due to 0 recurrences among patients with anti–HPV-16 E6 and E7 antibodies present.